Selective mastectomy in the management of locally advanced breast cancer

被引:2
作者
Ahern, Verity [1 ]
Boyages, John
Gebski, Val
Moon, Dominic
Wilcken, Nicholas
机构
[1] Westmead Hosp, Dept Radiat Oncol, Westmead, NSW 2145, Australia
[2] Westmead Hosp, Dept Med Oncol, Westmead, NSW 2145, Australia
[3] Westmead Hosp, Dept Surg, Westmead, NSW 2145, Australia
[4] Westmead Hosp, NSW Breast Canc Inst, Westmead, NSW 2145, Australia
[5] Univ Sydney, Clin Trials Ctr, NHMRC, Sydney, NSW, Australia
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2007年 / 68卷 / 04期
关键词
locally advanced noninflammatory breast cancer; mastectomy; radiotherapy; chemotherapy;
D O I
10.1016/j.ijrobp.2007.01.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate local control for patients with locally advanced noninflammatory breast cancer (LABC) managed by selective mastectomy. Methods and Materials: Between 1979 and 1996, 176 patients with LABC were prospectively managed by chemotherapy (CT)-irradiation (RT)-CT without routine mastectomy. All surviving patients were followed for a minimum of 5 years. Results: A total of 132 patients (75%) had a T4 tumor and 22 (12.5%) supraclavicular nodal disease. The clinical complete response rate was 91% (160/176), which included 13 patients who underwent mastectomy and 2 an iridium wire implant. The first site of failure was local for 43 patients (breast +/- axilla for 38); 27 of these patients underwent salvage mastectomy and 11 did not for an overall mastectomy rate of 23 % (40/176). If all 176 patients had undergone routine mastectomy (136 extra mastectomies), 11 additional patients may have avoided an unsalvageable first local relapse. The others would have either have not had a local relapse or would have suffered local relapse after distant disease. No tumor or treatment related factor was found to predict local disease at death. Median disease-free and overall survival for all patients was 26 and 52 months, respectively. Conclusions: Selective mastectomy in LABC may not jeopardize local control or survival. (C) 2007 Elsevier Inc.
引用
收藏
页码:1010 / 1017
页数:8
相关论文
共 66 条
[1]   The importance of postoperative radiation therapy in multimodality management of locally advanced breast cancer: A phase II trial of neoadjuvant MVAC, surgery, and radiation [J].
Abdel-Wahab, M ;
Wolfson, A ;
Raub, W ;
Mies, C ;
Brandon, A ;
Morrell, L ;
Lee, Y ;
Ling, S ;
Markoe, A .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 40 (04) :875-880
[2]  
Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
[3]   LOCALLY ADVANCED BREAST-CANCER - DEFINING AN OPTIMUM TREATMENT REGIMEN [J].
AHERN, V ;
BARRACLOUGH, B ;
BOSCH, C ;
LANGLANDS, A ;
BOYAGES, J .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 28 (04) :867-875
[4]   Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer [J].
Baldini, E ;
Gardin, G ;
Giannessi, PG ;
Evangelista, G ;
Roncella, M ;
Prochilo, T ;
Collecchi, P ;
Rosso, R ;
Lionetto, R ;
Bruzzi, P ;
Mosca, F ;
Conte, PF .
ANNALS OF ONCOLOGY, 2003, 14 (02) :227-232
[5]   Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: A European organization for research and treatment of cancer randomized phase III trial [J].
Bartelink, H ;
Rubens, RD ;
vanderSchueren, E ;
Sylvester, R .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :207-215
[6]   THE EFFICACY OF COMBINED CHEMOTHERAPY AND RADIOTHERAPY IN ADVANCED NON-METASTATIC BREAST-CANCER [J].
BOYAGES, J ;
LANGLANDS, AO .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1988, 14 (01) :71-78
[7]   Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience [J].
Brito, RA ;
Valero, V ;
Buzdar, AU ;
Booser, DJ ;
Ames, F ;
Strom, E ;
Ross, M ;
Theriault, RL ;
Frye, D ;
Kau, SW ;
Asmar, L ;
McNeese, M ;
Singletary, SE ;
Hortobagyi, GN .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) :628-633
[8]  
Buzdar A U, 1995, Surg Oncol Clin N Am, V4, P715
[9]   Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer [J].
Buzdar, AU ;
Ibrahim, NK ;
Francis, D ;
Booser, DJ ;
Thomas, ES ;
Theriault, RL ;
Pusztai, L ;
Green, MC ;
Arun, BK ;
Giordano, SH ;
Cristofanilli, M ;
Frye, DK ;
Smith, TL ;
Hunt, KK ;
Singletary, SE ;
Sahin, AA ;
Ewer, MS ;
Buchholz, TA ;
Berry, D ;
Hortobagyi, GN .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3676-3685
[10]  
CAUDRELIER JM, 2002, RADIOTHER ONCOL S1, V65, pS6